November 17, 2003
Chugai Pharmaceutical reported that results of PII studies conducted in the EU and Japan were presented at the 67th Annual Scientific Meeting of the American College of Rheumatology in New Orleans showing that MRA, a humanized antihuman interleukin-6 receptor monoclonal...read more